ZYUS Life Sciences Corp
- LAST PRICE0.7000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.7900 / 0.7000
- Day Range
- 52 Week Range
- Volume20,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZYUS |
|---|---|---|
| 02:39 ET | 5000 | 0.7 |
| 02:43 ET | 1000 | 0.7 |
| 03:12 ET | 2500 | 0.7 |
| 03:50 ET | 1500 | 0.7 |
| 03:51 ET | 2000 | 0.7 |
| 03:57 ET | 3000 | 0.7 |
Nov 4, 2024
ZYUS Life Sciences Corporation Announces Unsecured Loan, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ZYUS Life Sciences Corp | 59.5M | -1.3x | --- |
Biomind Labs Inc | 39.5M | -34.9x | --- |
Nurexone Biologic Inc | 46.6M | -5.9x | --- |
Alpha Cognition Inc | 48.6M | -1.7x | --- |
Briacell Therapeutics Corp | 29.7M | -1.9x | --- |
KDA Group Inc | 37.8M | -82.7x | --- |
Company Information
ZYUS Life Sciences Corporation is a Canada-based life sciences company. It develops and commercializes novel cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a highly purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its pre-and non-clinical studies provide the foundation for clinical investigations of its drug candidates in humans. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management.
Contact Information
- Headquarters
- 204 - 407 Downey RoadSASKATOON, SK, Canada S7N 4L8
- Phone
- 306-242-2357
- Fax
- 416-368-4440
Executives
- Chairman of the Board
- Charlotte Hepburn
- President, Chief Executive Officer
- Brent Zettl
- Chief Financial Officer
- Michael Kindy
- Independent Director
- Charles Burns
- Independent Director
- Michael Detlefsen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.1M |
|---|---|
Revenue (TTM) | $428.0K |
Shares Outstanding | 74.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.52 |
Book Value | $0.33 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 121.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -9,752.57% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
